Claims for Patent: 7,879,027

Summary for Patent: 7,879,027

Title:	Controlled release devices for fusion of osteal structures
Abstract:	A device includes a first reservoir configured to include a degradation agent, a first control element configured to provide access to the first reservoir, and an expandable component configured to extend to engage an osteal structure.
Inventor(s):	Trieu; Hai H. (Cordova, TN)
Assignee:	Warsaw Orthopedic, Inc. (N/A)
Application Number:	11/517,771
Patent Claims:	1. A device comprising: a first reservoir configured to include an osteogenerative agent; a second reservoir configured to include a degradation agent; a first valve in fluid communication with the first reservoir, wherein the first valve is configured to open in response to a first soft tissue condition of pressure or hydration and close in response to a second soft tissue condition; a second valve in fluid communication with the second reservoir, wherein the second valve is configured to remain closed during the first soft tissue condition and the second soft tissue condition and is configured to open in response to a third soft tissue condition; and an osmotic driver coupled to the first reservoir and the second reservoir. 2. The device of claim 1, wherein the second valve is configured to open upon implantation. 3. The device of claim 1, wherein the first soft tissue condition is a low pressure or hydration condition. 4. The device of claim 1, wherein the second soft tissue condition is a pressure or hydration condition higher that the first soft tissue condition. 5. The device of claim 1, wherein the third soft tissue condition is a pressure or hydration condition higher than the first soft tissue condition and the second soft tissue condition. 6. The device of claim 1, wherein the osteogenerative agent includes an osteoconductive agent. 7. The device of claim 1, wherein the osteogenerative agent includes an osteoinductive agent. 8. The device of claim 7, wherein the osteoinductive agent includes bone morphogenetic protein, demineralized bone matrix, transforming growth factor (TGF), osteoblast cells, growth and differentiation factor (GDF), LIM mineralized protein (LMP), platelet derived growth factor (PDGF), insulin-like growth factor (ILGF), or any combination thereof. 9. The device of claim 1, wherein the degradation agent includes chymopapain, collagenase, chondroitinase, keratanase, human proteolytic enzymes, papaya proteinase, or any combination thereof.

Details for Patent 7,879,027

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Discure Medical, Llc	CHYMODIACTIN	chymopapain	For Injection	018663	11/10/1982		2026-04-24
Discure Medical, Llc	CHYMODIACTIN	chymopapain	For Injection	018663	08/21/1984		2026-04-24
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2026-04-24